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Improving uniformity in brain death
determination policies over time
ABSTRACT
Objective: To demonstrate that progress has been made in unifying brain death determination
guidelines in the last decade by directly comparing the policies of the US News and World Re-
port’s top 50 ranked neurologic institutions from 2006 and 2015.
Methods: We solicited official hospital guidelines in 2015 from these top 50 institutions, gener-
ated summary statistics of their criteria as benchmarked against the American Academy of
Neurology Practice Parameters (AANPP) and the comparison 2006 cohort in 5 key categories,
and statistically compared the 2 cohorts’ compliance with the AANPP.
Results: From 2008 to 2015, hospital policies exhibited significant improvement (p 5 0.005) in
compliance with official guidelines, particularly with respect to criteria related to apnea testing
(p 5 0.009) and appropriate ancillary testing (p 5 0.0006). However, variability remains in other
portions of the policies, both those with specific recommendation from the AANPP (e.g., specifics
for ancillary tests) and those without firm guidance (e.g., the level of involvement of neurologists,
neurosurgeons, or physicians with education/training specific to brain death in the determination
process).
Conclusions: While the 2010 AANPP update seems to be concordant with progress in achieving
greater uniformity in guidelines at the top 50 neurologic institutions, more needs to be done.
Whether further interventions come as grassroots initiatives that leverage technological advan-
ces in promoting adoption of new guidelines or as top-down regulatory rulings to mandate speed-
ier approval processes, this study shows that solely relying on voluntary updates to professional
society guidelines is not enough. Neurology® 2017;88:562–568
GLOSSARY
AAN 5 American Academy of Neurology; AANPP 5 American Academy of Neurology Practice Parameters.
The determination of death by neurologic criteria, or brain death as it is commonly called, has
become codified through an extensive process over many decades.1–3 The medical community
has widely embraced and accepted brain death as a medical and legal diagnosis, and society has
placed trust in the medical community to ensure good process and high reliability in this
diagnosis.
The American Academy of Neurology (AAN) has taken the lead in providing guidelines and
practice parameters for brain death determination, starting with the 1995 AAN Practice Param-
eters (AANPP).4 However, members of our group who worked at different US institutions
became concerned that variability in hospital policies might exist, which could lead to inaccurate
brain death determination. We assessed this variability in 2008 in a study of the US News and
World Report top 50 ranked institutions for neurology and neurosurgery5 and indeed found
significant variability not only between hospitals but also with accordance to the current AANPP
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at that time. This led to an update of the
AANPP in 2010,6 which served not only to
validate the central tenets of the 1995 practice
parameters but also to be highly proscriptive in
the details of brain death determination,
including the provision of a detailed checklist
and description of how determination is accu-
rately performed. The mission of the guide-
lines was to provide a template that would
allow hospitals to incorporate these new guide-
lines and the checklist into their hospital pol-
icies, thereby helping to ensure a sound and
100% accurate process.
The purpose of this study was to re-evaluate
the top 50 ranked programs (as of 2015) to see
whether policies were being updated to be in
accordance with the current AANPP and
whether variability still exists.
METHODS Standard protocol approvals, registrations,
and patient consents. Informed consent and institutional
review board approval were not required because the study
involved no human participants and the guidelines were in the
public domain and not considered private property.
The 2008 policy data were obtained directly from our previ-
ous similar study, which provides further details on methodol-
ogy.5 For the 2015 data, we referenced the 2015 US News and
World Report top neurology and neurosurgery hospitals rankings.7
Data acquisition took place July 2015 to January 2016 through
solicitation of hospital policies via direct personal e-mail or assis-
tance from local organ procurement organizations. Institutions
were all provided assurance of anonymity of their policies and that
the purpose of the study was to provide summary statistics across
all institutions.
As in the original 20081 and expanded 20158 studies, we used
5 categories of data: determination performance (i.e., who was
qualified to determine brain death), prerequisites for testing, de-
tails of the clinical examination, details of apnea testing, and de-
tails of ancillary testing. Using this framework, we created
summary statistics for variability and commonality among
institutions.
Data from both 2008 and 2015 were then assessed for
a binary measure of compliance (either yes, precisely matched,
or no, did not match) with the official AANPP at the time (either
the 1995 AANPP for the 2008 cohort of policies or the 2010
update for the 2015 policies). Criteria for which the AANPP
did not provide specific guidance were excluded from this analysis
(e.g., waiting period between 2 examinations). A total of 55 pol-
icy criteria were assessed for 2015 hospitals and 57 for the 2008
cohort. The cohorts were then split into paired hospitals (those in
the top 50 at both time points with both policies obtained, n 5
29) and unpaired (n 5 9 unique 2008 policies and n 5 20
unique 2015 policies). Compliance data were compared by
use of paired-sample, 2-tailed t tests for the paired group and
2-sample, 2-tailed t tests assuming unequal variance for the
unpaired group. No change in rates of compliance was used as
the null hypothesis in both instances. p Values for these 2 groups
were then combined by use of the Fisher method.
RESULTS A total of 49 hospitals provided policies
for the 2015 arm; of these, all (100%) had official
guidelines for brain death determination at their insti-
tution. The 2008 study obtained 38 policies from 41
respondents, with 29 institutions contributing poli-
cies in both time periods. Of the 49 policies in the
2015 study, 76% had been instituted or revised at
a time after the June 2010 update to the AANPP,
while 16% did so before 2010 and 10% made no
mention of their date of revision (figure 1). Multiple
examinations were required in 71% of 2008 guide-
lines but only 61% of those in 2015.
Summary statistics.With regard to who was qualified to
perform brain death determination, 23 (47%) of the
2015 policies required some type of education (e.g.,
training) or competency specific to brain death, while
21 (43%) did not and 5 (10%) made no mention. Fur-
ther breakdown of specialties of providers found neurol-
ogy or neurosurgery attendings stipulated most
frequently, with 49% of policies explicitly encouraging
their participation, followed by primary attendings
(41%), an unspecific licensed physician (22%), intensiv-
ists (24%), and finally emergency medicine physicians
(6%), with a further 10% making no mention. (Note
that these percentages do not sum to 100% because
multiple policies mentioned more than one type of pro-
vider.) Of note, no policy in 2015 explicitly stated that
an advance-practice provider (e.g., nurse practitioner or
physician assistant) could determine brain death.
Most hospitals required 2 brain death examina-
tions (61%), with a minority requiring only one
(27%), requiting either 1 or 2 (8%), or making no
mention of how many (4%). Within the subset of
34 hospitals requiring 2 examinations, 28 (82%)
specified that 2 separate physicians (rather than the
same one) perform those examinations. A waiting
Figure 1 Year of most recent policy update/revision
The majority of institutions (74%) have updated their policies at a date after the June 2010
update to the American Academy of Neurology Practice Parameters (AANPP), while 16%did
not and 10% made no mention of revision date, suggesting that most institutions had an
opportunity to review the official guidelines before adopting their current policies, but
26% did not.
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period between the first and second examinations was
specified in 53% of those policies (18 of 34), with the
majority (14 of 18) stipulating a period of 6 hours.
Twenty-two percent of institutions also explicitly
stipulated a waiting period for patients experiencing
cardiac arrest. Sixty-four percent of these (7 of 11)
specified 24 hours.
The vast majority of policies (96%) established
prerequisites before a clinical examination was initi-
ated to rule out confounders. These included the
absence of hypothermia (94%); absence of drug effect
(92%); absence of confounding conditions such as
endocrine, acid-base, and electrolyte disorders
(90%); assurance that providers can identify the cause
of coma (90%); and establishment of the absence of
shock (82%) (figure 2).
Specifically within the prerequisite criteria looking
for the absence of drug effects, the 2015 policies
largely ruled out potential confounding from both
sedatives and paralytics (61%, plus 10% mentioning
both and another drug) vs a minority of policies look-
ing for only one or the other (6% sedatives, 2% para-
lytics, 2% paralytics 1 other). Thirty-seven percent
of policies also specified acceptable drug level thresh-
olds, and 31% stipulated the use of neuromuscular
testing (i.e., “train of 4”) to confirm the absence of
ongoing neuromuscular blockade.
The minimum temperature thresholds to qualify
for absence of hypothermia varied greatly, from
328C/908F (22%), 338C (4%), 34.38C/948F (2%),
358C (8%), 35.58C (2%), and 368C/978F (37%), to
36.58C (6%). Ten percent of policies did not specify
a minimum core temperature but acknowledged the
need for absence of hypothermia. Eighty-two percent
of institutions required absence of shock as a prereq-
uisite, but the definitions in the policies of a lowest
acceptable blood pressure ranged from systolic blood
pressures of 90 mm Hg (22%) or 100 mm Hg (22%)
to mean arterial pressures of 60 mm Hg (10%) and
65 mm Hg (2%). Forty-four percent of these institu-
tions requiring absence of shock did not define any
lower threshold for blood pressure. Finally, most pol-
icies (92%) required patients to have no confounding
medical conditions. Of these policies, 80% further
stipulated the absence of acid-base, endocrine, and
electrolyte derangements.
Within the clinical examination, the vast majority
of policies looked for the presence of coma (94%),
absence of pain response with peripheral stimulation
(94%), and absence of oculovestibular (94%), oculo-
cephalic (92%), corneal (94%), pupillary (94%),
cough (88%), and gag (88%) reflexes. Approximately
half of policies (43%) looked for specific pupil sizes in
the 4 to 9 mm (29%) or mid to dilated (6%) range.
Notably, consistently poor compliance was seen in
absence of reaction to pain above the foramen mag-
num (53%), lack of spontaneous respirations (47%),
and testing of the jaw jerk reflex (24%) (figure 3).
Figure 2 Prerequisites to testing
(A) The vast majority of 2015 policies (96%) required the perquisites listed by the American Academy of Neurology Practice
Parameters, but the policies contained high variability in details (e.g., [B] the definition of hypothermia).
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Apnea testing, in addition to the clinical examina-
tion, was required in all but one policy (98%), but the
specifics of the testing technique varied widely across
institutions. Sixty-one percent of 2015 policies speci-
fied a lowest acceptable body temperature (range
328C–36.58C), 86% specified the need for an arte-
rial blood gas measurement before starting, and 78%
specified preoxygenation. Most policies (69%) rec-
ommended maintenance of oxygenation via a cannula
placed inside the endotracheal tube; a small minority
permitted continued use of a mechanical ventilator on
flow-by oxygenation with no delivery of breaths (6%).
Supplemental oxygen rate during apnea testing was
specified in 69% of policies, with specific flow rates
ranging from 1 (3%), 4 (3%), 6 (56%), and 8 (6%) to
10 (9%) L/min and 100% fraction of inspired oxygen
(6%). It is not clear why one policy did not stipulate
apnea testing, and hospitals were not contacted for
clarification or explanations of specific aspects of their
policies.
A positive apnea test was specified by a final arte-
rial PCO2 of 60 mm Hg in 86% of 2015 guidelines
(one policy stipulated 55 mm Hg). A secondary
acceptable measurement of a rise in PCO2 above base-
line was specified in 71% of 2015 guidelines, with
100% of those policies referencing a minimum
increase of 20 mm Hg above the patient’s baseline.
Sixty-seven percent of policies instructed examiners to
stop apnea testing if the patient became unstable.
Relatively few policies (18%) provided guidance on
repeating apnea testing for inconclusive results or
instability on the first attempt (figure 4).
Ancillary testing was optional in a majority of the
2015 institutions (78%), recommended in 12%, and
unspecified in 10%. Eighty-four percent indicated
specific situations in which ancillary testing would
be recommended, most commonly related to an
inability to complete the clinical (73%) or apnea
(78%) testing, in addition to toxic drug levels
(49%), chronic CO2 retention (31%), and normal
neuroimaging (6%). A majority of policies specified
the use of the 4 AANPP-recommended ancillary
tests: EEG (86%), transcranial Doppler (71%), angi-
ography (80%), and radionuclide scintigraphy
(88%). Unproven ancillary tests were stipulated in
a minority of policies, specifically CT angiography
(12%) and somatosensory evoked potentials (10%).
In addition, relatively few policies gave specific in-
structions on how to administer these tests or to
interpret results (49% for EEG, 37% for transcranial
Doppler, 37% for angiography, and 43% for radio-
nuclide scintigraphy) (figure 5).
Compliance statistics. Overall, the 2015 hospitals
showed significant improvement in compliance with
the AANPP compared with the 2008 cohort (p 5
0.005, combined p value Fisher method). Looking
at the subgroup comparisons, in the paired group of
29 hospitals with policies obtained in both 2008 and
2015, overall compliance with the AANPP did not
Figure 3 Clinical examination compliance with AANPP, 2015 vs 2008
(A) Consistent compliance to the majority of the clinical examination is shown, with additional specificity for pupil size in
45% of policies. (B) Areas of notably poor adherence in 2008 and 2015. AANPP 5 American Academy of Neurology
Practice Parameters.
Neurology 88 February 7, 2017 565
ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
show statistical improvement (p 5 0.054, 2008 aver-
age compliance 5 59.3% vs 2015 5 68.0%). How-
ever, in the unpaired hospitals, compliance showed
a statistical improvement (p 5 0.011, 2008 average
compliance 5 52.9% vs 2015 5 72.0%).
Breaking this overall measure of compliance into
its subgroups of key categories of the brain death
examination shows that most of this improvement is
driven by increased uniformity in apnea testing and
ancillary testing. In the paired group, 51% of 2008
hospitals complied with apnea guidelines vs 63% in
2015 (p 5 0.072), and in the unpaired group, 42%
complied in 2008 vs 71% in 2015 (p 5 0.016).
Combined, the 2015 hospitals significantly improved
their compliance from 2008 (p 5 0.0091). Similarly,
for ancillary testing, both the paired and unpaired
groups significantly improved their compliance from
2008 to 2015 (paired: 53%–64%, p 5 0.020;
unpaired: 47%–71%, p 5 0.003, in combination
p5 0.0006). In contrast, compliance for prerequisites
to testing (64% to 68% from 2008 to 2015, com-
bined paired and unpaired p 5 0.500) and clinical
Figure 5 Policies in 2015, similar to 2008, continue to name ancillary tests much more frequently than
describing their specific details (e.g., 86% look for EEG as an ancillary test, only 49% stipulate
specifics)
Radionuclide scintigraphy appears in a notably greater proportion of 2015 policies (88%) than 2008 policies (66%) and
with greater details (43% scintigraphy specifics in 2015 vs 21% in 2008). Unproved tests (shaded gray) continue to be
endorsed by a minority of policies.
Figure 4 Apnea testing compliance with AANPP, 2015 vs 2008
Apnea testing criteria showed a notably higher proportion of policies requiring arterial blood gas (ABG) measurement before
beginning apnea testing (86% vs 66%) and a PCO2 rise of 20 mmHg above baseline for the test to qualify as positive (71%
vs 39%). Overall compliance to the American Academy of Neurology Practice Parameters (AANPP) guidelineswas greater in
2015 than in 2008 (p , 0.04).
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examination criteria (71% to 81%, combined p 5
0.0673) did not differ significantly.
DISCUSSION The findings of the original 2008
study1 on variability in brain death determination in
the United States drew attention to a lack of unifor-
mity among policies at highly ranked neurology and
neurosurgery institutions. Its publication spurred the
update of the AANPP in 2010,6 designed to be simple
and straightforward, conclusive, yet sufficiently
detailed for practical use. Disappointingly, 16% of
policies sampled in 2015 were last revised before
the June 2010 publication of the AANPP update,
and an additional 10% did not specify a date of
creation/revision. Thus, by default,.25% of institu-
tions might not have benefited from the AANPP
update.
In assessing progress made in improving policy
uniformity, we looked to 4 areas of concern high-
lighted by the 2008 study: low rates of neurologist/
neurosurgeon involvement, strikingly high variability
in numeric thresholds (temperatures, blood pres-
sures), details of apnea testing, and ancillary testing
specifics. The portions of policies detailing apnea test-
ing (p 5 0.0091) and ancillary testing (p 5 0.0006)
showed a statistically greater compliance to 2010
AANPP. This encouraging result is suggestive of an
effect of the revised brain death guidelines on hospital
policies, but this cannot be fully established. How-
ever, variability continued to be high in terms of
policies specifying neurology or neurosurgery involve-
ment, and it is conventional wisdom that a specialist
in the acute neurosciences would be preferred, but
comparative studies are not available and are difficult
to perform. Data from simulation scenarios suggest
differences between critical care and neurology
trainees.9
These results suggest primarily a good response to
the 2010 AANPP revision, which appears to have had
a positive effect on the content of individual institu-
tional policies. We suggest 2 possible theories for
why some policies have not been updated: a false
sense of security and lack of regulatory oversight driv-
ing change.
As the 2010 AANPP highlighted, although the
legitimacy of death determination by neurologic crite-
ria has faced some opposition since its inception,
there has never been a single reported case of recovery
of neurologic function after the clinical diagnosis of
brain death was made with full adherence to the
1995 AANPP.6 Given this tremendous nationwide
success of declaring death by neurologic criteria, hos-
pitals may be lulled into a false sense of security in the
validity and sufficiency of their existing policies.
However, this logical fallacy masks the fact that the
primary reason why the criteria have been afforded
accurate diagnosis is the regular, precautionary up-
dates that aim to identify what might lead to mis-
diagnosis before it can occur. Indeed, we know
from the 1981 President’s Commission that, by ear-
lier criteria, physicians would have misdiagnosed
toxic drug ingestions and other conditions as brain
death. The crucial detail in the success of brain death
determination thus far lies in its tremendous evolu-
tion since the original 1968 Harvard criteria and re-
affirms the importance of participation in this
iterative process at the local level.
Second, change is a costly, time-consuming process
for any institution, particularly voluntarily change that
may not directly influence a hospital financially.
Without enforced accountability for having up-to-
date brain death policies, institutions may understand-
ably react slowly and partially to any updates in
practice parameters. Aside from these broad theories,
explanations for lack of uniformity may be specific
to an institutional level. For example, the culture of
a particular hospital may wish to leave the details of
determination to the discretion of the physician.
This study made a key assumption that the adop-
tion of an official hospital policy for brain death deter-
mination is indicative of actual practice. That is, it is
assumed that the physicians practicing in those hospi-
tals made regular use of and adhered to those policies.
This is certainly not a guarantee at institutions em-
ploying many physicians at various stages of training
(who may also have spent time practicing the differ-
ent policies of a previous employer). It has been
shown that documentation of brain death determina-
tion also varies widely across hospitals.10 Therefore,
actual practice could be either more or less variable
than the policies suggest (e.g., if only a few physicians
within an institution diagnose the majority of brain
deaths and they mutually decide to follow the
AANPP criteria without changing the hospital policy
to match or vice versa). Another limitation is the
sample bias of only looking at highly ranked neuro-
logic institutions, which are not representative of
many smaller, community hospitals in the nation.
In addition, within the statistical analysis of this
highly ranked group, the sets of hospitals in 2008
and 2015 were only partially overlapping, with more
of the significance in improvements deriving from the
unpaired, nonoverlapping institutions.
For physicians to preserve the legitimacy of the
diagnosis of brain death and to maintain the public’s
trust in the medical community, brain death needs to
be accurately diagnosed 100% of the time. Patients
and their loved ones deserve the peace of mind of
knowing that to be true no matter where the diag-
nosis takes place. However, because even the top 50
neurologic institutions in one of the most medically
advanced nations are not in agreement after 2
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decades of efforts toward uniformity, room for
improvement remains.
Our recent study attempted to further quantify
the magnitude of variability in brain determination
of all hospitals with intensive care capabilities in the
United States.8 Among the 508 nationwide hospitals
it queried, a similar lack of consensus existed.8 Vari-
ability in brain death policies is a now a known
national problem, one that does not seem be ade-
quately addressed solely with an update to profes-
sional society guidelines. This raises deeper
questions of the current capacity of medicine to react
in a timely and unified way to changes in our under-
standing of best practices for patient care. Thus far,
one encouraging move to modernize and accelerate
the pace of policy updates is the Neurocritical Care
Society’s online tool kit for brain death, which in-
cludes an online course, video demonstrations of clin-
ical examination techniques, and sample policies and
checklists for institutions to easily adopt and imple-
ment.11 In addition, there are currently ongoing ef-
forts to create templates within existing electronic
medical records to improve the ease and accuracy of
documentation and to help ensure good practice.
However, beyond the promotion of user-friendly,
digital resources, The Joint Commission or the
Department of Public Health, in its ongoing assess-
ments of hospitals nationwide, may consider adding
the standardization of brain death determination to
its roster of requirements for accreditation. Regulatory
oversight, rather than voluntary participation, may be
the missing driver to accelerate AANPP adoption.
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